Next Article in Journal
Exogenous Melatonin Enhances Cold, Salt and Drought Stress Tolerance by Improving Antioxidant Defense in Tea Plant (Camellia sinensis (L.) O. Kuntze)
Previous Article in Journal
The Effect of Furanocoumarin Derivatives on Induction of Apoptosis and Multidrug Resistance in Human Leukemic Cells
Article Menu
Issue 9 (May-1) cover image

Export Article

Open AccessArticle

ICAM3-Fc Outperforms Receptor-Specific Antibodies Targeted Nanoparticles to Dendritic Cells for Cross-Presentation

1
Translational Nanobiomaterials and Imaging, Department of Radiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
2
Department of Tumor Immunology, Radboud Insititute for Molecular Life Sciences, Radboud University Medical Center, Postbox 9101, 6500 HB Nijmegen, The Netherlands
3
Department of Biochemistry and Molecular Biology, University of Barcelona, Diagonal 643, 08028 Barcelona, Spain
*
Authors to whom correspondence should be addressed.
Academic Editor: Fernando Albericio
Molecules 2019, 24(9), 1825; https://doi.org/10.3390/molecules24091825
Received: 9 April 2019 / Revised: 7 May 2019 / Accepted: 8 May 2019 / Published: 12 May 2019
(This article belongs to the Section Nanochemistry)
  |  
PDF [1537 KB, uploaded 12 May 2019]
  |     |  

Abstract

Optimal targeting of nanoparticles (NP) to dendritic cells (DCs) receptors to deliver cancer-specific antigens is key to the efficient induction of anti-tumour immune responses. Poly (lactic-co-glycolic acid) (PLGA) nanoparticles containing tètanus toxoid and gp100 melanoma-associated antigen, toll-like receptor adjuvants were targeted to the DC-SIGN receptor in DCs by specific humanized antibodies or by ICAM3-Fc fusion proteins, which acts as the natural ligand. Despite higher binding and uptake efficacy of anti-DC-SIGN antibody-targeted NP vaccines than ICAM3-Fc ligand, no difference were observed in DC activation markers CD80, CD83, CD86 and CCR7 induced. DCs loaded with NP coated with ICAM3-Fc appeared more potent in activating T cells via cross-presentation than antibody-coated NP vaccines. This fact could be very crucial in the design of new cancer vaccines. View Full-Text
Keywords: ICAM3-Fc; receptor-specific antibodies; targeting; nanoparticles; dendritic cells; cross-presentation ICAM3-Fc; receptor-specific antibodies; targeting; nanoparticles; dendritic cells; cross-presentation
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

  • Externally hosted supplementary file 1
    Doi: 10.20944/preprints201904.0118.v1
SciFeed

Share & Cite This Article

MDPI and ACS Style

Cruz, L.J.; Tacken, P.J.; van der Schoot, J.M.; Rueda, F.; Torensma, R.; Figdor, C.G. ICAM3-Fc Outperforms Receptor-Specific Antibodies Targeted Nanoparticles to Dendritic Cells for Cross-Presentation. Molecules 2019, 24, 1825.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top